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Recently, lignin has been used as a starting material for the development of 
nanoparticles (NPs) for different purposes, including for biomedical applications. In this 
study, the carboxylation of the native lignin was carried out towards the modification of 
carboxylated lignin NP (CLNPs) with a block copolymer made of poly(ethylene glycol) 
(PEG), poly(histidine) (PHIS) and cell-penetrating peptide (CPP). The success of the 
conjugation reactions was confirmed by the conversion of the zeta-potential (ζ-potential) 
values from negative values for the bare CLNPs to positive values after the surface 
functionalization. The prepared CLNPs showed spherical shape, good size distribution, 
moderate polydispersity, good stability in physiological media and low cytotoxicity in all 
the tested cell lines at a concentration up to at least 250 µg/mL, after 24 h of incubation. 
A poorly water-soluble cytotoxic agent, benzazulene (BZL), was loaded into the CLNPs, 
improving its release profiles at pH 5.5 and 7.4. Furthermore, the release of BZL was 
found to be pH-sensitive, with higher release rates at pH 5.5 than at pH 7.4. Consequently, 
the BZL-loaded CLNPs conjugated with PEG-PHIS-CPP (BZL@CLNPs-PEG-PHIS-
CPP) showed an enhanced antiproliferative effect in the different cancer cells (IC50 < 24 
µM) compared to a normal endothelial cell line (IC50 ≈ 45 µM) after 24 h incubation, 
making the CLNPs promising candidates for anticancer therapy. 
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Recentemente, a lignina tem sido utilizada como matéria-prima para o 
desenvolvimento de nanopartículas para diferentes fins, incluindo para aplicações 
biomédicas. Neste estudo, procedeu-se à carboxilação da lignina nativa tendo em vista a 
modificação de nanopartículas de lignina carboxilada (CLNPs) com um copolímero 
constituído por poli(etilenoglicol) (PEG) e poli(histidina) (PHIS). A superfície das 
CLPNs também foi funcionalizada com um Péptido de Penetração Celular (CPP). O 
sucesso das reações de conjugação foi confirmado pela conversão dos valores negativos 
do potencial zeta obtido para as CLNPs puras, para valores positivos após a 
funcionalização da superfície destas nanopartículas. As CLNPs apresentaram forma 
esférica, boa distribuição de tamanhos, polidispersão moderada, boa estabilidade em 
meios fisiológicos e baixa citotoxicidade em todas as linhas celulares testadas em 
concentrações até pelo menos 250 μg/mL, após 24 h de incubação. Um agente citotóxico 
pouco solúvel em água, benzazulina (BZL), foi encapsulado nas CLNPs, melhorando os 
seus perfis de libertação a pH 5,5 e 7,4. Além disso, a libertação de BZL foi sensível ao 
pH, com taxas de libertação mais elevadas a pH 5,5 do que a pH 7,4. Consequentemente, 
as CLNPs conjugadas com PEG-PHIS-CPP contendo BZL (BZL @ CLNPs-PEG-PHIS-
CPP) mostraram um efeito antiproliferativo aumentado nas diferentes células 
cancerígenas (IC50 <24 μM), em comparação com uma linha celular endotelial normal 
(IC50 ≈ 45 μM) após 24 h de incubação, o que torna as CLNPs alternativas terapêuticas 
promissoras para o tratamento do cancro. 
 
Palavras chave: Nanopartículas de lignina; Funcionalização; Encapsulação de fármacos; 
Libertação sensível ao pH; Efeito antiproliferativo 
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DLS dynamic light scattering 
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FBS fetal bovine serum 
FTIR fourier transformed infrared spectroscopy 
HBSS-HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC high-performance liquid chromatography 
LNPs lignin nanoparticles 
MES 2-(N-morpholino)ethanesulfonic acid 
MRI magnetic resonance imaging 
NPs  Nanoparticles 
NT  Nanotechnology 
PBS  phosphate buffer saline 
PEG  poly(ethylene glycol) 
PDI  polydispersity index 
PDT  photodynamic therapy 
PET/CT  positron emission tomography / computed tomography 
P-gp  P-glycoprotein 
pH  potential of hydrogen 
PHIS  poly(histidine) 
PNPs Polymeric Nanoparticles 
PSA  prostate-specific antigen 
PTT  photothermal therapy 
TEM  transmission electron microscopy 
THF  Tetrahydrofuran 
UV  ultraviolet rays 
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Conventionally, nanotechnology (NT) comprehend materials, devices and 
systems with the size of 1 to 100 nm, however many nanomedicines are within the 
submicron size of 100-1000 nm (1,2). Indeed, NT has been given new and better 
approaches to several diseases compared to the traditional ones (3–5). For example, NT 
showed to be useful for the treatment of neurodegenerative (6), autoimmune (7,8) and 
cardiovascular diseases (9,10), osteoporosis (11) and against bacterial infections (12). 
However, one of the main uses of NPs in medicine is as drug delivery systems, mainly 
for cancer therapy, by specifically directing NPs to target cancer cells (13,14).  
Cancer is still a leading cause of diseases worldwide, with 14.1 million new cases 
and 8.2 million deaths in 2012. It is also expected that the burden of cancer will increase 
to 23.6 million new cases per year by 2030 (15–17). Despite these alerting numbers, the 
main therapies include surgery, radiation and chemotherapy, which have disadvantages, 
such as lack of specificity and effectivity (18,19). In this context, NT appears as a new 
and encouraging approach, due to the possibility to specifically target cancer cells, 
increasing the therapeutic effectivity of the chemotherapeutic agents and decreasing their 
side effects (3). These targeting made by the NPs can be passive or active (19). Passive 
targeting is based on the physiologic alterations caused by the existence of a cancer tissue, 
including the enhanced permeability and retention (EPR) effect, and an acidification of 
the environment around the cancer cells, which allows the preferable accumulation of 
NPs in the neoplastic tissues and the degradation of pH-sensitive NPs, respectively 
(20,21). In addition, active targeting promote the uptake of NPs into the cancer cells by 
adding specific ligands to the NPs, such as CPP, that promotes the specific targeting and 
the NPs internalization into the cancer cells (18,19). 
Polymeric NPs (PNPs) have shown a great potential for cancer therapy, because 
of their capability to adsorb, encapsulate or conjugate the anticancer agent within or onto 
their surface. Also, their formulations include polymers that are hydrophobic, non-toxic 
and blood compatible and ligands that specifically target receptors overexpressed on 
cancer cells (22). 
Lignin is a biopolymer with great potential for the preparation of NPs (23), due to 
its large abundance in nature (24) and its encouraging characteristics, such as 
biodegradability, biocompatibility, good stability and the possibility to chemically 




modify its structure thanks to the presence of phenolic and aliphatic hydroxyl groups (23). 
At the same time, lignin nanoparticles (LNPs) demonstrated the ability to load different 
drugs and the possibility of being modified with targeting molecules, such as pH-sensitive 
polymers and targeting ligands, allowing a pH-responsive drug release and an increased 
cellular interaction with specific cells, respectively (23). According to this information, 
LNPs have shown an increasing potential to be used as delivery systems for anticancer 
therapy (25). 
The main aim of this monography was to study the potential of CLNPs, conjugated 
with CPP and NH2-PEG-PHIS as delivery systems to be used for cancer therapy. The 
specific aims were: (i) to synthetize carboxylated lignin and therefore prepare and 
characterize CLNPs; (ii) to functionalize CLNPs with the block copolymer NH2-PEG-
PHIS and CPP in order to prepare CLNPs-CPP and CLNPs-PEG-PHIS-CPP; (iii) to 
characterize and evaluate the size, surface charge, stability and cytotoxicity of the 
prepared CLNPs; (iv) to evaluate the loading of a poorly water-soluble cytotoxic 
compound, BZL, and its release profiles at different pH values (5.5 and 7.4); and, finally, 
(v) to study the antiproliferative effect of the BZL-loaded CLNPs using several cancer 










2. Review of Literature 
 
2.1. Biomedical Applications of Nanotechnology  
 
Since the NT emerged, in 1958 with Richard Feyman (3) , it has being used for 
several applications, including the agriculture, development of transportation, space 
engineering and the improvement of the electronic components. However, one of the 
fields in which NT has most revolutionized is medicine (3,4). NT comprehend materials, 
devices and systems with the size of 1 to 100 nm (Figure 2. 1), giving them unique 
properties (3,5).  
These singular properties of NT can be very useful in the treatment of several 
diseases such as neurodegenerative (6), autoimmune (7,8) and cardiovascular diseases 
(9,10) and osteoporosis (11). In the field of neurodegenerative diseases, the NT can 
improve the regeneration of the damaged neurons, protecting them, and enhance the 
delivery of specific drugs through the blood-brain barrier (3,6). For the autoimmune 
diseases, the NPs have been used to reverse the lack of specificity of the anti-
inflammatory treatments using specific peptides that bind to molecules overexpressed in 
the target cell, to protect the drugs from clearance (by modification of the surfaces) or to 
improve the transport across physiological barriers (7). For example, the use of lipid-
based NPs has been studied for multiple sclerosis due to their capacity to cross the blood-
Figure 2. 1 - Nanoscale and possible Nanostructures (image copied 
from https://ocg.cancer.gov/e-newsletter-issue/issue-11/translating-
cancer-targets-nanotechnology-based-therapeutics) 




brain barrier and the possibility to insert lipid-soluble drugs (e.g., glucocorticoids)  in the 
phospholipid membrane and the water soluble drugs (e.g., mitoxantone) in the inner core 
(8).  
NT can also be used in the diagnosis and therapy of cardiovascular diseases such 
as coronary artery disease (9,10), by providing molecular imaging approaches, such as 
the use of NPs-based fluorescence imaging or super-paramagnetic iron oxide particles in 
the magnetic resonance imaging (MRI) (9,10). Also, NPs attached with certain molecules 
showed to target specific receptors, endothelial cells or macrophages involved in 
atherosclerosis (9,10). Other strategies were studied, such as pH-responsive delivery of 
antioxidants or the use of polymeric nanocoatings in stents (10). Osteoporosis is another 
disease where mineral-based nanomaterials have been produced, including calcium 
phosphate and silica NPs, which showed promising results in the production of new bone 
or reverse the osteoclast activity (11). Other interesting application of NT is the tendon 
healing and regeneration, by increasing the drug penetration across the skin and 
functioning as a vector for delivering of genetic material and polysaccharides, such as 
chitosan (12). 
NPs have also been studied in order to decrease the antimicrobial drug resistance, 
because of their high surface-to-volume ratio that improves their interaction with 
microorganisms (26). Furthermore, several NPs by themselves showed antimicrobial 
properties, due to their anti-adhesion capacity that decreases the production of biofilms, 
oxidation or reduction properties with consequent production of reactive oxygen species, 
and also by altering the bacterial physiology, through the generation of holes in the cell 
wall, for example (26). Thus, the use of NPs, in particular the inorganic NPs, is very 
useful for fighting superbugs (26,27). NPs have also applications in the field of 
vaccination (27). For example, synthetic NPs can module the activity of antigen 
presenting cells, by encapsulating or releasing immunomodulators that increase the 
dendritic cell activation, and lead to a specific immune recognition and also acting as co-
adjuvants (27). 
As above mentioned, one of the main uses of NT in medicine is the use of NPs as 
drug delivery systems, leading to the reduction of side-effects and the amount of drug 
used, lower costs and reduced patients’ pain (3). This strategy is mainly used in cancer 
therapy by specifically targeting the different types of NPs (Figure 2. 2) to cancer cells 
(13,14), either by passive or active targeting (19). 
 




Passive targeting comprehends an increase of permeability and retention of 
macromolecules, including NPs, that results from the lacking of smooth muscle cells, 
which leads to a permanent vasodilation and therefore their accumulation in the neoplastic 
tissues (21). However, passive targeting cannot promote the uptake of NPs by the malign 
tissues, what is exactly what active targeting does. Thus, active targeting comprises the 
selective targeting of receptors overexpressed on cancer cells by conjugating ligands onto 
NPs’ surface, which promotes NPs’ internalization by triggering receptor-mediated 
endocytosis (19). These ligands can be antibodies or aptamers, which are single stranded 
DNA or RNA that binds to specific cell proteins or peptides. Ligands can also be peptides, 
such as CPP, a highly cationic peptide, composed by 5-30 amino acids that increases the 
drug translocation across cell membrane (18,19). The internalization of NPs can be made 
by direct diffusion, but the most common mechanism is based on endocytosis (Figure 2. 
3) (28). Besides the specific targeting, the NPs present other advantages, such as protect 
the drugs from degradation, increase the drug delivery to tumor cells and modulate the 
pharmacokinetic profiles of the drugs, for example (13). 
Figure 2. 2 - Possible NPs  variations and changes: material, 
type, surface and shape (14) 




Due to their great biocompatibility, biodegradability and non-toxicity, PNPs are 
the most studied particles. Their properties depend on the type of polymers used, which 
can be synthetic or natural (13). 
 
2.1.1. Types of Nanoparticles 
 
There are several types of NPs, that are useful for cancer therapy (Table 2. 1), due 
to their ability of passive and active targeting of cancer cells, improvement of 
pharmacokinetic properties of the drugs and reversion of the mechanism of drug 
resistance (e.g., by silencing drug resistance genes or proteins, like H1F1α and Bcl-2) 
(29). Therefore, NPs can offer many advantages such as selective drug accumulation in 
tumor sites, reduced amount of drug used and lower side effects (30). The main types of 
NPs used in cancer therapy are the polymeric NPs, the vesicle-based carriers (such as 
liposomes, micelles and dendrimers), the polymer-conjugates, the protein carriers, the 
inorganic NPs (such as metallic NPs) and the biologically-delivery NPs. However, the 
PNPs will be highlighted in this monograph (30).  
 
 
Figure 2. 3 - Mechanisms through which NPs can enter into 
target cells (28) 





Nanocarriers Properties Characteristics 
Solid Lipid NPs 
Release drug in acidic 
microenvironment of multidrug 
resistance cells 
Delivers anticancer drugs to 
overcome P-gp mediated 
multidrug resistance 
PNPs 
Versatile platform for controlled, 
sustained, and targeted delivery 
of anticancer agents including 
small molecular weight drugs 
and macromolecules (genes and 
proteins) 
Enhanced drug accumulation, 
reduction of tumor 
size/volume, increased animal 
survival rate in rat models, 
minimal cytotoxicity in cancer 
cell lines, high transfection 
activity, potential to overcome 
multidrug resistance 
Liposomes 
Composed of lipid bilayers 
encapsulating both hydrophobic 
and hydrophilic drugs, stealth 




preferential accumulation in 
tumor tissues via enhanced 
permeability, and retention 
effect to overcome drug 
resistance 
Micelles 
Small size, high payload 
capacity, greater solubilization 
potential for hydrophobic drugs, 
improved stability, long 
circulation 
Selective targeting, P-gp 
inhibitory action, altered drug 
internalization, and sub-
cellular localization properties 
Mesoporous 
silica NPs 
Inorganic nanocarriers with 
tunable size and shape, high 
drug loading due to high pore 
volume and surface area, 
multifunctionalization for 
targeted, and controlled delivery 




therapeutics at cellular levels 
for therapeutic, and imaging in 
cancer 
Table 2. 1 - Most common NPs used in cancer therapy (29) 







Unique optical, electrical, 
magnetic and/or electrochemical 
properties, inert, stable, ease of 
functionalization 
Circumvents drug resistance 
associated with over 
expression of ATP-binding 
cassette transporters, increased 
intracellular drug retention, 
enhanced loss of cell viability 
Gold NPs 
Shape and size dependent on 
electronic characteristics, 
versatile drug delivery system 
due to tunable optical properties 
Induces cellular DNA damage 
Quantum dots 
Semiconductor inorganic 
fluorescent nanocrystals, small 
(1–20 nm), and uniform size, 
high surface to volume ratio, 
surface conjugation with 
multiple ligands, biocompatible, 
fluorescence properties help real 
time tracks within target cells 
Release of toxic compounds 
(cadmium) and generation of 
reactive oxygen species can 
result in long term toxicity 
 
Generaly, PNPs present sizes ranging from 10 to 1000 nm and can be made of 
biocompatible and biodegradable polymers (31) that are flexible, lightweight, and non-
toxic to the human body, such as chitosan, gelatin or albumin. These NPs have therapeutic 
potential as drug delivery systems, and therefore, for cancer therapy. The drugs can be 
entrapped, encapsulated or attached to the NPs (31,32). The main advantages reside on 
the increase of the stability, efficiency and effectiveness of the drugs used, and the 
possibility to deliver higher concentrations of therapeutic compounds to the desired 
location, allowing the application of PNPs in fields such as vaccine delivery or tissue 
engineering (31). Furthermore, PNPs are superior to lipidic NPs, such as liposomes, due 
to the higher compatibility with various active agents and loading volume, a more 
controlled drug release and the nonexistence of phospholipids oxidation (33). 




One of the most common methods to produce PNPs is the dialysis or solvent 
exchange method. This method is surfactant free and allows the production of small and 
well distributed NPs. The polymer is dissolved in an organic solvent and placed into the 
dialysis membrane with proper molecular weight cut off. The solvent displacement leads 
to the polymer aggregation due to lower solubility and therefore to the formation of NPs 
(32). In Figure 2. 4, other methods for the preparation of PNPs are referred, including 
solvent evaporation, freeze and spray drying, fast evaporation, micro and mini emulsion, 
surfactant-free emulsion and controlled radical (32). 
 
2.1.2. Main uses of Nanotechnology in Medicine 
Despite its uses in electronics, transportation and energy,, NT is mostly known by 
its application in the medicine field, such as in neurodegenerative, inflammatory, 
cardiovascular and cancer diseases. Moreover, NT can combine the delivery of drugs and 




Figure 2. 4 - Several techniques to produce Polymeric NPs (32) 




2.1.2.1. Nanoparticles as Delivery Systems 
 
The most promising application of nanomaterials is the possibility to specifically 
target their content, delivering small drugs as well as macromolecules such as proteins, 
peptides or genes, with few side effects (36,37). This specific delivery is possible due to 
the modification or functionalization of the NPs (37).  
The different types of NPs can also be used for distinct applications (37). For 
example, metallic NPs can be linked to a fluorescent marker for drug delivery and 
imaging in magnetic resonance (37,38). Liposomes are also used in drug delivery, with 
the advantages of low cost production, wide range of morphologies and capability to 
encapsulate many types of therapeutic biomolecules (38). For example, cationic 
liposomal systems can transport charged structures such as DNA and RNA, due to the 
electrostatic interactions between the positively charged phospholipids and the negatively 
charged nucleic acids (39) . However, colloidal particles such as PNPs have attracted an 
increasing attention, in which a therapeutic agent can be embedded or encapsulated in 
their matrix or adsorbed or conjugated on their surface. Thus, PNPs are great carriers for 
biomolecules, drugs, genes and vaccines. However, they present some disadvantages, 
including short circulating life, being rapidly cleared by phagocytic cells (36) . This can 
be improved by modifying the NPs surface, for example by adsorbing PEG onto NPs 
surface. This increases nanoparticle blood circulation half-life, since the addition of PEG 
causes steric repulsion by creating hydrated barriers on nanoparticle surfaces, preventing 
their opsonization (36). Other hydrophilic polymers can be also used, such as 
polysorbates 80 and 20, poloxamers and polysaccharides, like dextran, that provide a 
cloud of hydrophilic and neutral chains at the NPs surface, repelling plasma proteins (36). 
 
2.1.2.2. Nanoparticles for Biomedical Imaging 
 
Several NPs are used for imaging purposes (Table 2. 2). For example, quantum 
dots, which are NPs constituted by inorganic semiconductor molecules, can emit 
florescence that depends on particle size, because of the movement of an electron from 
the conduction band to the valence band (band gap) when the excitation ends, leading to 
a release of energy (34). Also, superparamagnetic iron oxide NPs can be used in MRI as 
contrast agents (34,40). These NPs have a core made of iron oxide, usually with a 
hydrophilic coat, showing superparamagnetic behaviour that allows them to become 




magnetized when a magnetic field is applied (40). Several studies have been applying 
these NPs to prostate cancer treatment, for example (40). 
Area NPs types 








• Imaging of lymph nodes, lung 
blood vessels, and tumors. 
• Greater intensity and resistance 
to photobleaching compared 
with conventional methods. 
• Site-specific targeting via 
surface functionalization. 
• Sub-cutaneous imaging 
without surgical incisions. 
MRI 
Superparamagnetic 
iron oxide NPs 
Cancer 
Detection 
• Enhanced contrast for imaging 
of liver, lymph nodes, and bone 
marrow. 
• Paramagnetic properties that 
can alter magnetic resonance 
relaxation times of selected 
regions of fluids in vivo. 
 
2.1.2.3. Nanomedicines for Theranostic Applications 
 
Theranostic relies on the possibility to simultaneously diagnose and treat a disease 
(Figure 2. 5-A), being possible to real-time monitor the progress and efficacy of the 
treatment, thus allowing an individualized treatment and feedback (41). There are many 
types of theranostic carriers, such as gold, silver and magnetic NPs, nanoshells and 
nanocages, which can be functionalized with drugs, ligands or antibodies. The use of NPs 
can be combined with several noninvasive imaging methods, including MRI, computed 
topography, positron emission tomography/Computed Tomography (PET/CT), among 
others. (Figure 2. 5-B) (35,41).  
Table 2. 2 - Types of NPs used in biomedical imaging, their applications and 
characteristics (34) 





2.2. Cancer: Actuality and Future Perspectives 
 
Cancer is a disease in which the cells start to grow and spread uncontrollably, 
invading other organs and ultimately leading to the patient death (18). The stages in 
cancer progression are classified according to the size and extension of the tumor size and 
its ability to invade the nearby lymph nodes and/or other organs (18). The conventional 
treatment methods include surgery, radiation and chemotherapy. However, the 
chemotherapeutic agents target both normal and tumor cells due to the lack of specificity. 
In order to overcome this limitation, NT can be used as a strategy to target the drug 
delivery and minimize its side effects, by using ligands that target the overexpressed 
transporters and receptors on cancer cell membrane (18,19). 
 
2.2.1. Cancer Epidemiology: Incidence, Mortality, Prevalence and 
Future Goals 
 
Cancer is one of the diseases with highest incidence worldwide, with 14.1 million 
new cases in 2012 (15). Lung, breast, colorectal and stomach cancers comprise more than 
40% of the total number of new cases. In men, lung and prostate cancer are the most 
common, whereas the breast cancer is the most incident in women (Figure 2. 6). 
Additionally, cancer caused 8.2 million deaths in 2012, more than half due to lung, 
stomach, liver, colorectal and breast cancers. Among the 32.5 million people diagnosed 
with cancer between 2007 and 2012, 6.3 million women had breast cancer, 3.9 million 
Figure 2. 5 - Nanotheragnostics: A- Scheme of a nanotheranostic agent; B- 
Approaches of nanotheranostic in cancer therapy (35) 




men had prostate cancer, and the colorectal cancer was diagnosed in 3.5 million men and 
women (15–17).  
In addition to all these numbers, the burden of cancer is expected to increase to 
23.6 million new cancer cases per year by 2030, which represents an increase of 68% 
compared with 2012 (15). 
 
2.2.2. Cancer Therapies: Actual and New Perspectives 
 
For almost all cancers, the main therapies include surgery, radiation and 
chemotherapy. However, due to their lack of specificity and effectivity, several efforts 
are being made to find new therapeutic solutions, mainly in the field of specific targeting 
therapy (18,19). 
 
2.2.2.1. Breast Cancer 
 
Breast cancer is the most frequent and lethal cancer in women (42). The diagnostic 
methods include mammography, MRI, ultrasound and PET/CT (42).The main modalities 
for breast cancer treatment include surgery, radiation therapy, chemotherapy and targeted 
therapy. Surgery is normally used in localized breast cancer and it is accompanied by 
neoadjuvant/adjuvant therapy to ensure fully recovery and decrease the risk of metastasis. 
Radiotherapy, a process in which radiation is applied to the cancer cells, can be combined 
with chemotherapy after surgery. Additionally, endocrine therapy can also be 
Figure 2. 6 - Most prevalent types of cancers by country, for males and females (15) 




systemically administered in order to lower the hormone levels or block the hormone 
receptors expressed on the cancer cells. However, systemic therapies (e.g., chemo and 
endocrine therapies) can often cause side effects, such as hair loss, gastrointestinal 
disturbances, neutropenia, and immunosuppression, with a negative impact in the 
patients’ quality of life. These problems led to several efforts aiming for the development 
of alternative treatments such as targeted drug delivery systems. These drug delivery 
systems showed to overcome the systemic toxicity and poor bioavailability problems 
associated with the antineoplastic drugs (43). The NPs can be used as contrast agents for 
imaging purposes, as drug carriers, as radiosensitizers or by inducing hyperthermia, 
causing apoptosis in the malignant tissues (42). 
 
2.2.2.2. Prostate Cancer 
 
Currently, prostate cancer is diagnosed in more than 1 million men per year 
worldwide and it was responsible for 307.000 deaths in 2012 (44). The diagnosis of 
prostate cancer can be done by screening of prostate-specific antigen (PSA) levels. PSA 
is an enzyme produced only by prostate cells, but it is not specific for prostate cancer, 
because the PSA levels can also be elevated in other pathologies, such as prostatitis, 
prostate abscess and prostatic infection (45). The main types of treatment are 
prostatectomy (removal of prostate), radiotherapy, brachytherapy (insertion of a 
radioactive source directly into the prostate) and hormone therapy (first option for non-
metastatic tumors) (44,45). However, most of these treatments can cause side effects or 
lead to cancer recurrence and resistance to the posterior treatments (44). Thus, the use of 
drug carriers, particularly liposome, PNPs and metallic NPs, have been investigated in 
order to overcome these limitations (44). 
 
2.2.2.3. Colorectal Cancer 
 
Colorectal cancer is the third most commonly diagnosed type of cancer with 20–
25% of the patients presenting metastasis at the time of diagnosis, usually done by 
colonoscopy (46). Because of that, most of the patients have palliative treatment instead 
of curative, since the neoplasm is already in an advanced stage when it is diagnosed 
(46,47). Several systemic drugs have been used for the treatment of colorectal cancer, 
such as 5-fluorouracil, irinotecan, oxaliplatin and some monoclonal antibodies 




(bevacizumab, cetuximab and panitumumab) and their combination have shown some 
improvement in the treatment. The guidelines also recommend surgery, immunotherapy 
and radiotherapy, all of them possible to be used in combination (46). Additionally, NPs 
have been studied for diagnosis and treatment purposes, using nanobioconjugates as 
contrast agents (e.g., tunable quantum dots) for fluorescence-based imaging techniques, 
as well as, through the use of NPs (e.g., gold NPs) to specifically deliver cytotoxic drugs 
into cancer cells, increasing their effectiveness and reducing the side effects (47,48). 
 
2.2.3. Use of Nanomedicines in Cancer Therapy 
NT is an emerging tool in cancer therapy through the use of nanobioconjugates 
composed by NPs and specific molecules for diagnostic or therapeutic purposes, such as 
contrast agents, chemotherapeutic drugs and targeting ligands. The stability of 
nanobioconjugates in blood can vary from hours to days, depending on the surface 
proteins, which can prevent the aggregation or agglomeration process, protecting them. 
As already mentioned, these nanobioconjugates can act by passive and/or active targeting 
(Figure 2. 7) (47,49). The passive targeting occurs due to the bigger fenestrations 
between the endothelial cells that surround the cancer cells than the normal cells, so called 
EPR effect., which allows the extravasation of NPs with sizes between 100 to 600 nm and 
their accumulation in the tumor tissue (47,50). Also, due to the high metabolism exhibited 
by cancer cells, the environment around them is more acidic than in normal cells, which 
allows the degradation of pH-sensitive NPs (stable at a physiologic pH), releasing active 
drug only in acidic environments, such as in tumor cells (20). However, the active 
targeting can effectively deliver the payloads to the cancer cells, in which the nanocarriers 
functionalized with antibodies, peptides and nucleic acids can specifically bind to the 
receptors in the surface of target cells (47). This targeted delivery of drugs through 
nanobioconjugates leads to a decreased toxicity of the drug in normal tissues as well as a 
reduced multidrug resistance (50). For example, studies shown that NPs may solve the 
problem of P-glycoprotein (P-gp) related multi-drug resistance (51,52), since the drug 
molecules associated with a nanocarrier would be released slowly in cancer cells, 
avoiding the activation of drug resistance-related genes. Also, NPs are considered a poor 
substrate for P-gp, allowing drugs to remain inside the cells, where their anti-cancer 
activities are most effective (53). Others strategies studied were the use of NPs containing 




a siRNA-mediated silencing of P-gp (54) or the use of the copolymer Eudragit, specially 
Eudragit S100, as excipient for NPs preparation (52). 
Because of such properties, nanobioconjugates can be used for diagnostic or 
treatment purposes or combine both modalities for theranostic applications (35). 
 
2.2.3.1. Use of Polymeric Nanoparticles in Cancer Therapy 
 
PNPs are colloidal particles in which an anticancer agent can either be 
encapsulated within their polymeric core or adsorbed, or conjugated onto NPs surface 
(22). For their formulation, hydrophilic, non-toxic and biocompatible polymers can be 
used, such as polyvinyl alcohol and PEG. Furthermore, PEGylation can prevent the 
process of phagocytosis and opsonisation by providing a hydrophilic coating on the NPs’ 
surface (22). Thus, the anticancer can be localized within the hydrophobic core of the NPs 
surrounded by a hydrophilic shell, increasing their systemic circulation time, and thereby, 
their persistence in the bloodstream. Several ligands can be used to functionalize the NPs, 
including small molecules, peptide, proteins, antibodies, engineered antibody fragments, 
Figure 2. 7 – Schematic representation of the passive and active targeting (49) 




and aptamers, that target specific receptors expressed on the membrane of cancer cells 
and/or endothelial cells present in the tumor vasculature (22). For example, folate 
receptors, epidermal growth factor receptors and the transferrin receptors are mostly 
present on cancer cells, while integrins, vascular cell adhesion molecule-1, 
aminopeptidase N/CD13, membrane type 1 matrix metalloproteinase and vascular 
endothelial growth factor receptors, are mostly expressed on the vasculature of tumor 
cells (22,55). 
Other polymers have been investigated as delivery vectors of chemotherapeutics 
into cancer cells, including polypeptides (e.g., poly (L-lysine)), natural (e.g., chitosan, 
dextran and hyaluronic acid, for example) and synthetic (e.g., polyamidoamine) polymers 
(55). In fact, PNPs tend to accumulate in specific organs. For example, dextran sulphate 
binds to more receptors on liver sinusoidal endothelial cells than hyaluronic acid and thus 
it accumulates more in the liver (56). Other example are NPs coated with anionic poly 
(glutamic acid)-based peptides that show tissue-specificity to spleen and bone (57). 
 
2.3. Lignin as a Starting Biomaterial for an End-use 
Applications 
 
The term lignin derives from Latin word lignum, which means wood (24). Lignin 
is one of the three components of lignocellulosic biomass, along with cellulose and 
hemicellulose. Lignin is the second most abundant natural substance in nature after 
cellulose, (24,58) and an abundant renewable source of aromatic polymers on earth. 
Lignin has been studied for 30 years because of its attractive characteristics such as high 
content in aromatic structure, wide availability and potential to be modified (59). 
However, lignin is a challenging starting material to work with due to its characteristics, 
such as complex macromolecular structure that depends on its botanic origin, isolation 
procedure and high molecular heterogeneity within the same batch (59). Despite of these 
challenges, several high-value products obtained from lignin have been produced, such 
as vanillin, dimethyl sulfoxide, active carbon and carbon fibers (58) . According to that, 
lignin has been used for end-use applications, which are summarized in Figure 2. 8 (58). 





2.3.1. Biologic Origin and Degradation of Lignin 
 
From an evolutionary point of view, the presence of lignin in the plant structure 
enables the development of the tracheid cell type, permitting a better transportation of 
water in the plant and the expansion of plants into dryer land (60). So, the fraction of 
lignin varies according to the different sources of biomass. The highest lignin fraction is 
typically found in softwood which ranges between 25 and 32 wt%, while in hardwoods 
is slightly lower (18–25%) (60). For grass is even lower, and it is almost absent in mosses 
and green algae, which reflects the major milestones of evolution of lignin biosynthesis 
(Figure 2. 9) (60,61). 
Lignin is typically composed by three different monomers called monolignols: p-
coumaryl, coniferyl and sinapyl alcohols. When incorporated into the lignin structure, 
these monolignols originate units that are commonly referred as hydroxyphenyl (H), 
guaiacyl (G) and syringyl (S) units, respectively (61). 
 
Figure 2. 8 - Several end-use applications of lignin (58) 





The initial step for the biosynthesis of the lignin building blocks is the formation 
of cinnamic acid from phenylalanine, through the action of the enzyme phenylalanine-
ammonia-lyase. Cinnamic acid is then converted into the three basic monolignols and 
after to the respective units through several reactions (60), including dehydrogenations, 
reductions, hydroxylases and transference of several chemical groups, such as methyl 
groups (Figure 2. 10) (61). Afterwards, the polymer is formed after enzymatically 
catalysed oxidation of the phenol groups of the monolignols, which originates monolignol 
radicals that polymerize into the basic building blocks of the lignin polymer (60). The 
relative proportions of the building blocks vary depending on the type of biomass. For 
example, the guaiacyl unit is dominant in softwoods (90–95%), but the amount of syringyl 
units (45–75%) is bigger than the guaiacyl units in hardwoods. Lignin in grasses contains 
significant amount of p-hydroxyphenyl units (5–35%), which is practically absent in both 
softwoods and hardwoods (60). 
Figure 2. 9 - Evolution of lignin biosynthesis represented by a plant 
phylogenetic tree (61) 





2.3.2. Structure and Characterization of Lignin 
 
As above mentioned, the lignin monomers are called monolignols and consist of 
phenylpropanolic units that present different degrees of substitution of the methoxy 
groups on the aromatic ring, as shown in Figure 2. 11 (59). 
Figure 2. 10 - Synthesis of the different types of units present in the 
lignin structure (61) 
Figure 2. 11 - The monolignol monomers species present in 
the lignin structure (59). 




The primary structure of lignin is formed by radical polymerization of 
monolignols by peroxidases and lactases that lead to the formation of an important variety 
of inter-unit linkages. The β-O-4’ ether linkages are the most abundant and involve the 
binding of the β carbon of one unit with the phenolic hydroxyl group of the other unit. 
Other linkages include α-O-4’ ether and 4-O-5’ diphenyl ether, for example (59,60). 
According to this, the proportions of the three monomer types in lignin influences the 
type of inter-unit linkages, which also determines the degree of branching and the 
reactivity of lignin (59,60). 
However, the structure of lignin in nature is different from the lignin obtained as 
a co-product in the industrial cooking process, used to solubilize the nature lignin, 
insoluble in water, and thereby separate it from the fiber fraction, forming technical lignin 
(60). Its structure is also dependent on the cooking method applied (60). Therefore, the 
proportion of the different linkages present in technical lignins will be different from 
those existing in the native lignin (60). Technical lignins are divided into two categories, 
according to their sulfur content. The first one includes the sulphur-containing 
commercial lignins, such as lignosulfonates and kraft lignins, which can be produced in 
large quantities. The second one includes lignins without sulphur in their composition, 
such as organosolv and soda lignin (62). These lignin can be further used as a substrate 
for chemical functionalization in order to produce high value products (59). 
 
2.3.3. Valorisation and renewal of Lignin 
 
Lignins and their derivatives have been included in many pharmacological studies 
(Table 2. 3), which showed their potential for the treatment of diabetes and emphysema, 
to control obesity, as well as used as anticoagulant, (23), antiviral, antioxidant, prebiotic 
and antibiotic (23,58). In addition, natural lignin is considered to be part of dietary fiber 










Compound Effect Mechanism 
Experimental 
Model 
Alkali lignin Antidiabetic 
α-amylase inhibition  
In vitro decreased 
glucose diffusion 







Decrease blood glycemia 
In vitro inhibitor of 
α-glucosidase  
Rat in vivo 
Antiviral 
activity 
Inhibition of the 
replication of herpes 
simplex virus (HSV) 
Infected mice by 
exposing scarified 
skin to an HSV-2 G 
Binding to the HIV-1 
envelope glycoprotein 
In vitro cells: T-









Inhibiting viral binding 
and penetration 
Vero cells infected 
with herpes simplex 
virus 
Binding the HIV-1 
envelope glycoprotein 
HeLa cells infected 
with herpes simplex 
virus 
Lignophenols Obesity control 
Decrease oleate-induced 
apo-B secretion 
HepG2 cells in vitro 
Decrease plasma 
triglyceride levels 






Inhibition of thrombin Binding to thrombin 





and mouse arterial 
thrombosis models 
Antiemphysema 
Elastase, oxidation and 
inflammation inhibition 
In vitro human 




Table 2. 3 - Main pharmacological activities of lignins and their derivatives (23) 




However, lignin valorization is also applied in biorefinery processes (63,64). 
Currently, most lignocellulosic biorefineries use enzymes to decompose plant 
polysaccharides to produce lignin-rich streams by separating the lignin in the solid state 
from the others plant carbohydrates or by applying pretreatments to fractionate biomass 
to extract lignin (63). The pretreatments of biomass can consist on using dilute sulfuric 
or other acids, or simply hot water (hydrothermal) to break down hemicellulose to sugars 
and to increase cellulose accessibility for enzymatic hydrolysis, after which most of the 
lignin is left in the solid residue. In other pretreatment methods, high pH conditions are 
applied to dissolve a large portion of the lignin (63). Other treatments consist of using 
microbial conversion, using specific microbes to catalyze the degradation of a 
heterogeneous mix of aromatic molecules to single products, such as lignin (64).  
After extraction of lignin, this compound can be used in several industrial 
applications. For example, lignin products have been studied to be a platform for the 
global development of energy-efficient lightweight vehicles, since lignin has become an 
ideal precursor for carbon fiber synthesis, using different types of reactions, such as 
oxidations or pyrolysis, as described in Figure 2. 12 (63). 
Another lignin application is for the production of plastics and composites (63). 
For example, formulations either without chemical modification of lignin, including 
phenol-formaldehyde resins, polyolefin, polyester polymers, polyurethanes and bio-
plastics, or with chemical modifications, such as lignin-based epoxy resins for wood 
adhesion, have been used to produce different materials, including mineral wool; 
stabilized materials against photo-oxidative degradation, as well as other ecofriendly 
products (58). Lignin have also been studied to produce other high-value materials than 
carbon fiber, such as vanillin, dimethyl sulfoxide and active carbon (63). 
Figure 2. 12 - Thermal treatment applied to convert lignin into carbon fibers (63) 




2.3.4. Chemical Modifications of Lignin 
 
Lignin is a very good candidate for the development of new materials due to the 
presence of phenolic and aliphatic hydroxyl groups in its structure (23). For example, 
phenolic hydroxyl groups and aliphatic groups at C-α and C-γ positions enable the lignin 
utilization as a substitute for phenol in the synthesis of phenolic resins, for example (65). 
Other chemical modifications involving the reactivity of hydroxyl groups on the natural 
polymer are esterification and etherification reactions. In addition, the introduction of 
reactive amine groups in the lignin has been considered as one of the most promising 
processes, since the aminated lignin can be employed in the preparation of polyurethane 
or epoxy resins. (66). 
The epoxidation of lignin has also been gaining importance for the production of 
epoxy resins, which can be used for adhesives, composites and coatings (62). 
Other type of chemical modification of lignin is the carboxylation (67), which will 
be used in this project before the preparation of the NPs. 
  
2.3.5. Preparation of Lignin Nanoparticles 
 
According to the extraction methods, there are different types of lignins, such as 
kraft lignin, soda lignin, lignosulphonate and organosolv lignins (68,69), as represented 
in Figure 2. 13. 
Although each lignin class has a specific chemical structure and particular 
properties, lignin possesses unique properties such as resistance to biological attacks, UV 
absorbance, high stiffness, and antioxidative properties, showing promising potential to 
produce high value products, including NPs. At the same time, most lignins are only 
soluble in water at alkaline pH, which is a major limitation for its application at an 
industrial scale (69). Despite of this, lignin has been shown potential for preparing LNPs 
(69). 
Lignin is indeed one of the most abundant biopolymers in nature, being 
biodegradable, biocompatible and it presents very good stability, which makes it an ideal 
precursor for the development of environmentally friendly nanomaterials, suitable for 
being used as stabilizers in cosmetic and pharmaceutical formulations and for drug 
delivery of anticancer compounds (23,25). Also, innovative LNPs have shown others 




features, important for drug delivery and biomedical applications, such as the ability to 
carry hydrophobic drugs and sustain their release, as well as good cellular interactions 
(23,25). As a result of their surface structure, LNPs can also be modified with targeting 
molecules in order to increase cellular interaction with specific cells for cancer therapy, 
for example. Also, pH-sensitive polymers can be added to the LNPs to allow pH-
responsive drug release (23,25). 
 
2.3.5.1. Preparation Methods of Lignin Nanoparticles 
 
LNPs have been previously synthesized using several methods, including solvent 
exchange (that can produce both solid and hollow particles), antisolvent precipitation, 
sonication, polymerization, interfacial crosslinking, aerosol processing and CO2 
precipitation (69). In the antisolvent precipitation method, the precipitation of the solute 
is achieved by decreasing the solvent power for the solute dissolved in a solution, adding 
a non-solvent for solute called as antisolvent (70).  
Figure 2. 13 - General characteristics of the different types of lignin: A) extraction 
processes of each type of lignin; B) Physical and chemical characteristics of each 
type of lignin (68) 





For example, the solvent exchange method is often performed by dialysis and 
antisolvent precipitation method are initiated with acids (71). Initially, exchange method 
was done by dialysis using ethylene glycol as a solvent, which resulted into irregular NPs 
(72). However, other studies have shown the possibility of preparing NPs, like LNPs, 
with an acceptable average diameter, prepared from soft wood kraf lignin dissolved in 
tetrahydrofuran (THF), introduced into a dialysis bag immersed in excess of deionized 
water during 24 hours (25,72). 
The physical properties of these particles such as hydrophobicity, surface charge, 
and stability are dependent on the type of lignin used and the nanoparticle preparation 
method (71). 
 
2.3.5.2. Delivery Systems for Biomedical Applications 
 
As already referred, LNPs exhibit important features for drug delivery and 
biomedical applications, such as the possibility for carrying hydrophobic drugs (such as 
BZL and sorafenib) (25). Another very important characteristic of these LNPs is the 
possibility for being modified by targeting molecules in order to increase the cellular 
uptake by specific cells (23,25). All these characteristics make lignin an ideal starting 
material for the development of environmentally friendly nanomaterials that can be used 
for anticancer therapy (25). For example, LNPs loaded with BZL and sorafenib showed 
inhibitory effects on different cancer cells including MDA-MB-231 and MCF-7 (human 
breast cancer cell lines), PC3-MM2 (a prostate cancer cell line), Caco-2 (colorectal 
adenocarcinoma) (25). These LNPs also showed a moderately uniform dispersity, 
biocompatibility, very good stability, good cellular interaction, a time and dose-
dependent cellular uptake, an improvement of the release profiles of both drugs at 
different pH-values and an enhancement of the antiproliferative effect of BZL in different 
cell lines (25).  
According to this study, LNPs showed potential as delivery systems for cancer 
therapy. In the future, the addition of pH-sensitive polymers to these LNPs can induce a 
pH-responsive release of drugs which is an important strategic to be studied for cancer 
therapy (25).  




3. Aims of the study 
 
Several studies have shown the potential of lignin as a polymer for NPs 
production, due to its abundance and biodegradable characteristics. Given the potential 
already demonstrated of LNPs for anticancer therapy, the main aim of this study was to 
evaluate the characteristics and potential CLNPs as a delivery system of anticancer 
compounds.  
 
 The specific objectives of this monography were as follow: 
 
1. To synthetize carboxylated lignin, and therefore, prepare and characterize CLNPs. 
 
2. To conjugate the CLNPs with the block copolymer PEG-PHIS and CPP in order 
to prepare CLNPs-CPP and CLNPs-PEG-PHIS-CPP, using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide 
(EDC/NHS) coupling chemistry.  
 
3. To characterize the prepared CLNPs by dynamic light scattering (DLS) and 
transmission electron microscopy (TEM), and to evaluate their stability in human 
plasma and cell culture media, as well as in vitro cytotoxicity in different cell 
lines: MDA-MB-231 (human breast cancer cell line), PC3-MM2 (a prostate 
cancer cell line), Caco-2 (colorectal adenocarcinoma) and EA.hy926 (a non-tumor 
endothelial cell line). 
 
4. To evaluate the loading and release profiles of a poorly water-soluble cytotoxic 
compound, BZL, at different pH values (5.5 and 7.4).  
 
5. To realize in vitro antiproliferative studies of the BZL-loaded CLNPs using the 
cell lines mentioned above. 
  




4. Materials and Methods 
 
4.1. Material and Cell Culturing 
 
LignoBoost™ softwood kraft lignin was obtained from Stora Enso (Finland). BZL 
(8-isopropyl-1-methyl-4-(trifluoromethyl)-3H-benzo[cd]azulen-3-one) was synthetized 
as described elsewhere (73). CPP was purchased from GenicBio (China), α-t-
butyloxycarbonylamino-ω-carboxy succinimidyl ester (Boc-NH-PEG-NHS; MW = 4928 
Da) from Iris Biotech GmbH, and Poly(hystidine) (PHIS; MW = 14200 Da) from Sigma-
Aldrich. Other materials and cell culturing are described in detail in Supporting 
Information. 
 
4.2. Carboxylation of Lignin 
 
Carboxylated lignin was prepared in order to increase the amount of carboxylic 
groups on the lignin structure for further conjugation reactions. For that, 100 mg of 
LignoBoost™ softwood kraft lignin was reacted with 100 mg of succinic anhydride and 
20 mg of 4-dimethylaminopyridine (DMAP ) in 40 mL of THF at room temperature for 
48 h. Then, the reaction mixture was dialyzed against MilliQ-water using a dialysis bag 
(Spectra/Por® 1 Standard RC Dry Dialysis Tubing, 12-14 kDa, Spectrum Labs, USA) 
during 24 h to remove the unreacted reagents, replacing the water periodically. Finally, 
the carboxylated lignin was freeze-dried and characterized with a Fourier transformed 
infrared spectroscopy (FTIR) instrument (Vertex 70, Bruker, USA) using a horizontal 
attenuated total reflectance (ATR) accessory (MIRacle, PIKE Technologies, USA). The 
ATR-FTIR spectra were recorded at room temperature between 4000−650 cm−1 with a 









4.3. Synthesis of Poly(Ethylene Glycol)-Block-Poly (ι-
Histidine) (NH2-PEG-PHIS) 
 
The block copolymers were synthetized and characterized as previously reported 
(74). Briefly, first the conjugation between Boc-NH-PEG-NHS and PHIS was made, and 
after, the deprotection of Boc-NH-PEG-PHIS was carried out (Figure S1). The detailed 
protocol can be found in Supporting Information. 
 
4.4. Carboxylated Lignin Nanoparticles Preparation 
 
The CLNPs were prepared by solvent exchange. Briefly, the carboxylated lignin 
was dissolved in THF and introduced into a dialysis bag (Spectra/Por® 1 Standard RC 
Dry Dialysis Tubing, 12-14 kDa, Spectrum Labs, USA). The CLNPs were formed during 
the dialysis process, where the THF soluble and water non-soluble carboxylated lignin 
molecules self-assembled into colloidal spheres as THF was gradually replaced by 
deionized water (72). The dialysis water was periodically replaced during 24 h and the 
dialysis was performed under slow stirring in a fume hood. 
 
4.5. Characterization of Carboxylated Lignin 
Nanoparticles 
 
CLNPs were characterized for their average particle size (Z-average), 
polydispersity index (PDI), and average ζ-potential (surface charge) by DLS using a 
Malvern Zetasizer Nano ZS instrument (Malvern Instruments Ltd, UK). For that, the 
samples were diluted in MilliQ-water (100 µg/mL for the size determination and 10 
µg/mL for the ζ-potential determination). To characterize their morphology and confirm 
their size distribution, the CLNPs were observed by TEM (TEM, Jeol JEM-1400, Jeol 
Ltd., Tokyo, Japan) using an acceleration voltage of 120 kV. For the sample preparation, 
a droplet of CLNPs’ suspension was placed on a carbon-coated copper grid, blotted using 
a filter paper, and then air-dried before analysis. 
The stability of CLNPs was assessed in Dulbecco's Modified Eagle medium 
(DMEM) and human plasma. For that, samples were withdrawn at 5, 10, 30, 90 and 120 




min after incubation of 300 µg/mL of CLNPs with the different media at 37 °C, and 
diluted in water to evaluate changes on the size of CLNPs over time. All the experiments 
were performed in triplicates. 
 
4.6. Conjugation of Carboxylated Lignin Nanoparticles 
with NH2-PEG-PHIS and CPP 
 
The conjugation reaction between the –COOH groups of carboxylated lignin and 
–NH2 groups of NH2-PEG-PHIS and CPP was performed in 10 mM of 2-(N-
morpholino)ethanesulfonic acid (MES) buffer pH 5.5, using EDC/NHS coupling 
chemistry. The mass ratios of polymer/peptide for the conjugation reactions were chosen 
after optimization of the conjugation conditions. In order to prepare CLNPs conjugated 
with CPP (CLNPs-CPP), 1 mg of CLNPs was suspended in 400 µL of 10 mM of MES 
buffer (pH 5.5), with 2.5 µL of EDC (20 mM, MW = 155 Da) and 2.3 mg of NHS (50 
mM, MW = 115 Da), and stirred at 500 rpm for 1 h at room temperature in the dark to 
activate the carboxylic groups on the CLNPs. Then, the mixture was centrifuged to 
remove the exceeding EDC/NHS, at 13200 rpm for 5 min, and the CLNPs were 
resuspended with 1 mL of 1× Hanks’ balanced salt solution with 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HBSS-HEPES, pH 7.4) containing 0.2 mg of CPP (mass 
ratio CPP:CLNPs of 1:5). The mixture was stirred at 500 rpm and room temperature 
during 4 h and afterwards centrifuged to separate the functionalized CLNPs from the free 
CPP. Finally, the CLNPs-CPP were washed twice with HBSS-HEPES (pH 7.4). 
For the preparation of the CLNPs conjugated with NH2-PEG-PHIS and CPP 
(CLNPs-PEG-PHIS-CPP), 1 mg of CLNPs was activated for 1 h, using the same 
conditions as described above. After removing the exceeding EDC/NHS, the CLNPs were 
resuspended with 1 mL of 10 mM of MES buffer (pH 5.5) with 0.1 mg of NH2-PEG-
PHIS dissolved (mass ratio co-polymer: CLNPs of 1:10), and the mixture was reacted 
during 4 h at 500 rpm,  and at room temperature. Then, the mixture was centrifuged to 
separate the functionalized CLNPs from the free co-polymer, and the CLNPs-PEG-PHIS 
were resuspended with 400 µL of HBSS-HEPES (pH 7.4), with 2.5 µL of EDC (20 mM, 
MW = 155 Da) and 2.3 mg of NHS (50 mM, MW = 115 Da). The mixture was stirred 
during 1 h at 500 rpm and at room temperature, in the dark to activate the carboxylic 
groups of the CLNPs-PEG-PHIS. After removing the unreacted products by 




centrifugation, 1 mL of HBSS-HEPES (pH 7.4) containing 0.2 mg of CPP (mass ratio 
CPP:CLNPs-PEG-PHIS of 1:5) was added to CLNPs-PEG-PHIS, and the mixture was 
stirred for 4 h at 500 rpm and at room temperature. Lastly, the CLNPs-PEG-PHIS-CPP 
were centrifuged and washed twice with HBSS-HEPES (pH 7.4). 
Besides the characterization by DLS, the functionalized CLNPs were also 
evaluated by ATR-FTIR. 
 
4.7. Cell Viability Studies 
 
Human umbilical vein cell line (EA.hy926), human mammary carcinoma cell 
lines (MDA-MB-231 and MCF-7), human prostate cancer cell line (PC3-MM2), and 
human colorectal adenocarcinoma cell line (Caco-2) were seeded in 96-well plates 
(PerkinElmer Inc., USA) at a density of 15000 cells per well and allowed to attach 
overnight. Afterwards, 100 µL of CLNPs, CLNPs-CPP and CLNPs-PEG-PHIS-CPP 
suspensions in cell media at different concentrations (50, 100, 250 and 500 µg/mL) were 
added to each well and the plates were incubated during 24 h at 37 °C. Incubations with 
cell media and 1% (v/v) Triton X-100 were used as a positive and negative controls, 
respectively. After that, the plates were equilibrated at room temperature for 30 min and 
the wells were washed once with 100 µL of HBSS–HEPES buffer. Then, 50 µL of Cell 
Titer-Glo® (Promega Corporation, USA) were added to 50 µL of HBSS–HEPES (pH 
7.4) in each well. The plates were stirred for 2 min on an orbital shaker and then stabilized 
for 30 min at room temperature, protected from the light. Finally, the luminescence was 
measured using a Varioskan Flash plate reader (Thermo Fisher Scientific Inc., USA). The 
number of viable cells in culture was quantified based on the amount of ATP produced 
by metabolically active cells (25,75). 
 
4.8. Loading of BZL 
 
Here, a poorly water-soluble cytotoxic agent (BZL), was used as model to test the 
drug loading into CLNPs. For that, 2 mg/mL of carboxylated lignin dissolved in THF 
were mixed with 400 µg of BZL dissolved in THF (weight ratio drug:lignin of 1:5), and 
then introduced into a dialysis bag (Spectra/Por® 1 Standard RC Dry Dialysis Tubing, 
12-14 kDa, Spectrum Labs, USA). The BZL-loaded CLNPs (BZL@CLNPs) were formed 




during the dialysis process using MilliQ-water (periodically replaced), for at least 24 h in 
order to remove THF and free BZL.  
The conjugation reactions of BZL@CLNPs with CPP and PEG-PHIS-CPP were 
performed according to the procedure described above for the empty CLNPs. The 
resulting NPs were termed BZL@CLNPs-CPP and BZL@CLNPs-PEG-PHIS-CPP.  
The BZL loading into CLNPs was determined by immersing the drug-loaded 
CLNPs in ethanol for 30 min under vigorous stirring to degrade the CLNPs. After 
centrifugation at 13200 rpm for 5 min, the supernatant was collected in order to determine 
the BZL concentration by using high-performance liquid chromatography (HPLC; 
Agilent 1100 series, Agilent Technologies, USA). The experimental conditions used for 
quantification of the loaded BZL are described in detail in Table S1 (25). 
 
4.9. In vitro Release Studies 
 
BZL was used to evaluate the in vitro release profiles of free BZL, BZL@CLNPs, 
BZL@CLNPs-CPP and BZL@CLNPs-PEG-PHIS-CPP, performed in sink conditions in 
two different buffers: 1× HBSS–MES (HBSS–MES, pH 5.5) and HBSS–HEPES (pH 
7.4), with 2% (v/v) of Tween 80. For that, 70 µg of pure BZL and 250 µg of BZL-loaded 
CLNPs were immersed in 60 mL and 20 mL of release media, respectively, and the 
samples were stirred at 150 rpm and 37 ºC. At the scheduled time intervals (2, 5, 10, 15, 
20, 30, 60, 120, 180, 240, 360 min and 24 h), 200 µL of the release media were withdrawn 
and the same volume of fresh pre-heated release media was added, keeping the releasing 
volume constant. Afterwards, the samples were centrifuged at 13200 rpm for 3 min (room 
temperature, 25 ºC) and the supernatant was collected and analyzed in HPLC. The amount 
of BZL released was determined by measuring the BZL concentration using the HPLC 
method detailed in Table S1. The average values were obtained from at least three 
replicates. 
 
4.10. Cell Antiproliferative Studies 
 
The cell growth inhibition was evaluated after 24 h incubation at 37 ºC of pure 
BZL and BZL@CLNPs, BZL@CLNPs-CPP and BZL@CLNPs-PEG-PHIS-CPP with 
different cell lines. Briefly, MDA-MB-231, PC3-MM2, Caco-2 and EA.hy926 cells were 




seeded in 96-well-plated at a density of 15000 cells per well and incubated overnight at 
37 ºC to allow the cells to attach. After that, 100 µL of suspensions containing different 
concentrations of BZL-loaded CLNPs (5, 10, 25, 50 and 100 µg/mL) and the respective 
concentrations of pure BZL previously dissolved with 1% ethanol (1.6, 3.3, 8.2, 16.4 and 
32.9 µM) in cell media were added to each well. Incubations with cell media and 1% (v/v) 
Triton X-100 were used as a positive and negative controls, respectively. A specific 
control for pure BZL was also added with the same amount of ethanol used in the 
dilutions. After the incubation, the number of viable cells in culture was determined using 
the CellTiter-Glo® luminescence cell viability assay kit (Promega Corporation, USA), 
and the luminescence was measured using a Varioskan Flash plate reader. All the 
experiments were performed at least in triplicate. 
 
4.11. Statistical Analysis 
 
The measured values are expressed by mean ± standard deviation (s.d.) of at 
least three independent experiments. One-way analysis of variance (ANOVA) with the 
Bonferroni’s post hoc-test was used to estimate the significant difference with a 
probabilities set of *p < 0.05, **p < 0.01 and ***p < 0.001, using the GraphPad Prism 
(GraphPad software Inc., CA, USA). 
  




5. Results and Discussion 
 
5.1. Carboxylation of Lignin 
 
Carboxylated lignin was prepared to increase the amount of carboxylic groups 
on the lignin surface for further conjugation reactions. For that, the hydroxyl groups of 
native lignin were reacted with succinic anhydride, with DMAP as catalyst (76).The 
possible mechanism for the carboxylation reaction is shown in Figure 5. 1-A. First, the 
nucleophilic attack of DMAP on a carbonyl group of succinic anhydride leads to the 
formation of a tetrahedral intermediate, which is more activated towards a nucleophilic 
attack to the hydroxyl groups on lignin than the original anhydride. Then, the lignin 
hydroxyl groups react with the intermediate to give another intermediate that will 
collapse, and the pyridine group is eliminated to obtain carboxylated lignin (77) 
To confirm the success of the carboxylation reaction, the ATR-FTIR spectra of 
CL and native lignin were compared and analyzed (Figure 5. 1-B). Both lignin and 
carboxylated lignin displayed the typical bands corresponding to the presence of different 
functional groups, such as alcoholic and phenolic –OH (3500–3100 cm-1), carbonyl 
groups (1600 cm-1) and aromatic structure (1427–1512 cm-1) (78). However, the CL 
showed a stronger absorption band at ca. 1720 cm-1 than the native lignin, mainly because 
of the stretching vibrations of C=O of the unconjugated –COOH groups. This can also be 
due to the stretching vibrations of C=O that derive from the ketone group situated at β-
location, which is also present in the native lignin, represented by the shoulder in the same 
region of the spectrum (78). The description of the main lignin functional groups, their 














5.2. Characterization of Carboxylated Lignin 
Nanoparticles 
 
After carboxylation of the native lignin, CLNPs dispersed in water were formed 
by solvent exchange, using the same dialysis method reported in previous studies 
(25,72,79). Using EDC/NHS coupling chemistry, the CLNPs were functionalized NH2-
PEG-PHIS to simultaneously increase the circulation in the bloodstream of the NPs due 
to the PEGylation effect, by preventing their opsonization, detection, and clearance by 
macrophages, and also to provide a pH-responsive behavior by using PHIS (80,81). In 
addition, the CLNPs were also modified by covalent binding of polyarginine R9 CPP, a 
small peptide with a high positive charge that allows the translocation through the 
negatively charged cellular plasma membrane (82). Afterwards, the bare and 
functionalized CLNPs were characterized by measuring their average size, PDI and ζ-
potential (Figure 5. 2-A and 5.2-B). The bare CLNPs size was 240 ± 22 nm, while the 
CLNPs-CPP and CLNPs-PEG-PHIS-CPP presented and average size of 375 ± 22 nm and 
373 ± 14 nm, respectively. A slight increase in the average size was observed for the 
Figure 5. 1 - (A) Schematic representation of the lignin 
carboxylation reaction. (B) ATR-FTIR spectra of 
native lignin (black) and carboxylated lignin (red). 




functionalized CLNPs as a result of the conjugation reactions. Regarding the size 
distribution of the three types of CLNPs, the PDI values were below 0.25, indicating a 
moderate dispersity of the resulting CLNPs. The size distribution and morphology of the 
prepared CLNPs were also studied by TEM (Figure 5.2-C). Even though the particles 
exhibited an average size similar to the values found by DLS, some discrepancies between 
the DLS and TEM measurements were observed, confirming the moderate dispersity of 
the prepared CLNPs. This phenomenon was previously reported in the literature, and it is 
explained by the fact that the DLS highlights the larger particles in the whole sample; but 
when observing the sample by TEM, it is possible to visualize some small particles that 
are not determined by DLS (25,83). In addition, the CLNPs showed symmetric and 
spherical shape, due to the appropriate interaction between the lignin and water during 
the solvent exchange process. 
Regarding the surface charge, the ζ-potential value obtained for bare CLNPs was 
-36 ± 4 mV, because of the –COOH groups present on the surface of CLNPs (Figure 5. 
2-B). However, a conversion of the ζ-potential to positive values was observed after the 
conjugations, where the CLNPs-CPP and CLNPs-PEG-PHIS-CPP showed 27 ± 10 and 
Figure 5. 2 - Characterization of CLNPs and functionalized CLNPs 
by: (A) measuring their average size and PDI; (B) ζ-potential, and 
(C) TEM images of CLNPs and CLNPs-PEG-PHIS-CPP. 




34 ± 3 mV, respectively, suggesting that the reactions of CLNPs with NH2-PEG-PHIS 
and CPP were successfully achieved. Both PHIS and CPP are positively charged due to 
the presence of –NH2 groups. 
Additionally, ATR-FTIR was performed to determine the chemical groups present 
on the surface of the particles and evaluate the differences between the bare CLNPs and 
the functionalized CLNPs (Figure 5. 3). For the undecorated CLNPs and conjugated 
CLNPs, the absorption band at around 1720 cm-1 was observed, because of the C=O 
stretching vibrations of the unconjugated –COOH groups. However, CLNPs-CPP and 
CLNPs-PEG-PHIS-CPP showed a characteristic band absorbing near 1670 cm-1, 
corresponding to the C=O stretching vibrations of the amide bond (O=C–NH), with minor 
contributions from the out-of-phase C–N stretching vibration, the C–C–N deformation 
and the N–H in-plane bend (84,85). Simultaneously, a decrease in the intensity of the 
band at 1720 cm-1 was observed when compared to the bare CLNPs. Furthermore, a small 
peak at ca. 1640 cm-1 also appeared, which is assigned to the –NH2 groups present on 
CPP and PHIS (86). The ATR-FTIR spectrum of the mixed CLNPs and PEG-PHIS (so-
called physical mixing) was also evaluated in order to compare with the conjugated 
CLNPs-PEG-PHIS-CPP. In the physical mixing, the absorption bands were slightly 
different from the observed for the CLNPs. Furthermore, the characteristic band at 1670 
cm-1 of the C=O stretching vibrations corresponding to the amide bond formation did not 
appear and a stronger band near 1640 cm-1 was present due to the NH2 groups on the 
PHIS. 
Thus, the ATR-FTIR spectra, together with the obtained ζ-potential values for the 
bare and conjugated CLNPs, suggested the success of the conjugation reactions. 
 





5.3. Stability of Carboxylated Lignin Nanoparticles 
 
The extent and specificity of serum/plasma protein binding to the surface of the 
NPs in physiological environment is influenced by the composition, size, shape and 
surface chemistry of the particles (e.g., surface charge), affecting their biodistribution in 
the body (87). The long-term binding of proteins on the NPs leads to formation of a “hard 
corona”, while the reversible binding of proteins that have faster exchange rates forms a 
“soft corona” (88). Therefore, the stability of the CLNPs was evaluated in biological 
media by measuring the changes on the size of the NPs. For that, the CLNPs were 
incubated in DMEM, supplemented with 10% of heated inactivated fetal bovine serum 
(FBS) and human plasma at 37 °C for 2 h (Figure 5. 4).  
Concerning the stability of CLNPs in DMEM supplemented with 10% FBS, an 
increase of 200 nm in the CLNPs’ size was observed during the first minutes of 
incubation, indicating some protein adsorption onto the NPs’ surface due to the FBS 
proteins. However, the size of the bare CLNPs decreased to the initial size, whereas the 
size of the conjugated CLNPs was kept constant over time.  Due to the positive charge of 
the conjugated CLNPs, the electrostatic effect between the NPs and the proteins of 
opposite surface charge can favor the formation of a soft corona that keeps constant over 
time (88,89). Regarding the human plasma, the size of the conjugated CLNPs had a higher 
increase than the bare CLNPs during the early minutes of incubation, which suggests a 
protein adsorption onto the CLNPs after contact with human plasma. After 10 min of 
Figure 5. 3 - Characterization of bare CLNPs and functionalized CLNPs 
by ATR-FTIR 




incubation, the size decreased substantially for the conjugated CLNPs due to the slow 
detachment of the adsorbed proteins that were weakly interacting with the hard protein 
corona layer. Here, the surface charge seems to play an important role in the interaction 
with the serum/plasma proteins (88,89). It is known that positively charged NPs have a 
short blood circulation half-life, because the proteins adsorbed on the surface of the NPs 
promote opsonization and, consequently, a rapid clearance from the bloodstream (88,90). 
Although there is PEG on the composition of the CLNPs-PEG-PHIS-CPP, the positive 
charge of the PHIS in outer part of the NPs can have a stronger effect than the PEG, or 
the PEG density on the surface of the NPs is not enough to limit the adsorption of proteins 
(91). 
 
5.4. In vitro Cytotoxicity 
 
Different NPs’ properties (e.g., size, shape, and composition and surface charge) 
can affect the cell-NP interactions and, consequently, their cytotoxicity.(92,93). In order 
to study the in vitro cytocompatibility of the prepared CLNPs, different concentrations of 
bare and functionalized CLNPs up to 500 µg/mL were incubated during 24 h with several 
cancer cell lines: MDA-MB-231 (Figure 5. 5-A), PC3-MM2 (Figure 5. 5-B), and Caco-
2 (Figure 5. 5-C) cells. These cancer cell lines were selected based on the therapeutic 
effect of the selected cytotoxic compound in the treatment of breast, prostate and 
colorectal cancers, respectively (94,95). In addition to that, a non-tumor EA.hy926 
Figure 5. 4 - Effect on the size of CLNPs, CLNPs-CPP and CLNPs-PEG-PHIS-CPP 
after 2 h incubation in (A) DMEM supplemented with 10% of FBS and (B) human 
plasma at 37 °C. Errors bars represent mean ± s.d. (n = 3). 




endothelial cell line was also chosen to evaluate the cytotoxic effect of the different 
CLNPs in a healthy cell line (Figure 5. 5-D). 
All the tested concentrations of CLNPs before and after functionalization showed 
a very good cytocompatibility after 24 h of incubation with more than 80% of cell 
viability, with exception for the highest concentration of CLNPs (250 and 500 µg/mL) 
after incubation with Caco-2 cells, which showed an increased toxicity to the cells. After 
conjugation with CPP, the surface charge of CLNPs changed from negative to positive 
values, and no statistically significant differences were observed when compared with the 
bare CLNPs, with the exception of the Caco-2 cells. Although some studies have been 
shown that the positively charged NPs can increase the interactions with the negatively 
charged cell membrane surface, others have reported that the surface charge of the NPs 
appears to play no role (96–98). The same trend was observed after conjugation of CLNPs 
with PEG-PHIS and CPP, which resulted in the production of positively charged NPs, 
without causing toxicity to the tested cell lines. Here, the effect of the PEGylation may 
be inhibiting the cell-NP interactions and the cellular uptake due to the steric hindrance 
(99). 
Figure 5. 5 - Cell viability of MDA-MB-231 (A), PC3-MM2 (B), Caco-2 (C) and EA.hy926 
(D) cell lines after incubation with CLNPs, CLNPs-CPP and CLNPs-PEG-PHIS-CPP at 
different concentrations for 24 h at 37 °C. The viability was determined by the Cell Titer-
Glo® luminescence assay and all data sets were compared to the positive control (different 
cell media). Errors bars represent the mean ± s.d. (n ≥ 3). The level of the significant 
differences was set at probabilities of *p < 0.05, **p < 0.01 and ***p < 0.001. 




5.5. Loading of BZL and In Vitro Release Study 
 
In this study, a poorly water-soluble cytotoxic agent (BZL) was used as a model 
drug to study the potential of the functionalized CLNPs as a drug delivery system. For 
that, the BZL-loaded CLNPs were prepared by dialysis method, and the conjugations with 
PEG-PHIS and/or CPP were carried out afterwards. The characterization of the BZL-
loaded CLNPs is summarized in Table 5. 1. In general, the size of the CLNPs after 
loading was slightly higher than the empty CLNPs. BZL@CLNPs, BZL@CLNPs-CPP 
and BZL@CLNPs-PEG-PHIS-CPP presented an average size of 295 ± 25, 402 ± 24 and 
438 ± 56 nm, respectively. With exception of BZL@CLNPs-PEG-PHIS-CPP, the PDI 
values of the BZL-loaded CLNPs were lower than 0.25, indicating again a moderate 
dispersity of the prepared CLNPs. In addition to that, the ζ-potential values of the CLNPs 
and drug-loaded CLNPs did not change significantly after loading. 
The loading degree and encapsulation efficiency of BZL was determined by 
releasing the cargo after suspending the NPs in ethanol for 30 min and analyzing it by 
HPLC. The loading degree of BZL in the CLNPs, CLNPs-CPP and CLNPs-PEG-PHIS-
CPP was 11 ± 1, 10 ± 1 and 9 ± 1%, respectively, decreasing along the conjugation 
reactions. Similarly, the encapsulation efficiency also decreased during the conjugations, 
being 57 ± 7, 50 ± 5 and 50 ± 10% for BZL@CLNPs, BZL@CLNPs-CPP and 
BZL@CLNPs-PEG-PHIS-CPP, respectively. 
Table 5. 1 - Characterization of BZL-loaded CLNPs before and after the 
conjugation with PEG-PHIS and/or CPP in terms of average size, PDI, ζ-potential, 
loading degree (LD) and encapsulation efficiency (EE). Results as presented as 











BZL@CLNPs 295 ± 25 0.21 ± 0.04 34 ± 3 11 ± 1 57 ± 7 
BZL@CLNPs-
CPP 
402 ± 24 0.23 ± 0.10 20 ± 7 10 ± 1 50 ± 5 
BZL@CLNPs-
PEG-PHIS-CPP 
438 ± 56 0.34 ± 0.03 42 ± 3 9 ± 1 50 ± 10 
 
The release profiles of pure BZL and BZL-loaded CLNPs were evaluated in two 
different aqueous buffers, HBSS-MES (pH 5.5) and HBSS-HEPES (pH 7.4), mimicking 
the tumor microenvironment and the physiological pH, respectively (Figure 5. 6-A and 




5. 6-B). To keep the sink conditions during the release, 2% (v/v) of Tween 80 was added 
to the release media.  
For the pure BZL, the release of BZL at pH 5.5 was slightly slower than at pH 7.4, 
being ca. 26 and 47% after 6 h, but the dissolution of BZL reached a plateau around 48% 
after 24 h in both pH values tested. However, when loaded into CLNPs, the BZL 
dissolution was strongly improved, particularly at pH 5.5, in which it reached ca. 100% 
after 24 h. At pH 7.4, a decreased amount of BZL was released from the CLNPs after 24 
h, when compared with the BZL released from the CLNPs at pH 5.5, which can be due 
to the precipitation or degradation of BZL.  
The release of BZL from the three types of CLNPs in both pH-values presented 
the following rate: BZL@CLNPs > BZL@CLNPs-CPP > BZL@CLNPs-PEG-PHIS-
CPP. Here, the functionalization of the CLNPs with the block copolymer or peptide seems 
to slightly slow down the release of BZL from the conjugated CLNPs, acting as a drug 
release barrier. Alternatively, ionic interactions between the drug and the attached block 
copolymer or peptide can also affect the release of BZL (100). In addition, the release of 
BZL from CLNPs showed a pH-responsive behavior, being released more efficiently at 
pH 5.5: the BZL@CLNPs-PEG-PHIS-CPP showed a sustained release of BZL when 
compared to the BZL@CLNPs and BZL@CLNPs-CPP. This can be due to the presence 
of a protonable nitrogen on the imidazole ring of PHIS that when it is protonated leads to 
a change on the conformation of the block-copolymer on the surface of the CLNPs, 
allowing the drug release (74,81). Overall, these nanosystems showed an enhancement 
on the dissolution rate and a pH-responsive release of the tested hydrophobic cytotoxic 
BZL compound, by a diffusion mechanism through the lignin structure (25). 
 Figure 5. 6 - Release profiles of pure drug and drug-loaded CLNPs, CLNPs-CPP and 
CLNPs-PEG-PHIS-CPP in (A) HBSS–MES (pH 5.5) and (B) HBSS–HEPES (pH 7.4), 
containing 2% Tween 80 at 150 rpm and 37 ºC for 24 h. Errors bars represent the mean ± 
s.d. (n = 3). 





5.6. Cell Antiproliferative Study 
 
The antiproliferative effect of the BZL-loaded CLNPs was studied after the 
loading capacity of BZL into CLNPs and their release profiles were evaluated. BZL 
inhibits the oncogenic Pim kinases that are often overexpressed in some solid tumors, 
including prostate and colon cancers, triggering the tumor development (73,94,95). Here, 
we used MDA-MB-231, PC3-MM2 and Caco-2 cells to represent the breast, prostate and 
colon cancers, respectively. Additionally, a non-tumor endothelial cell line (EA.hy926) 
was also tested in order to compare the toxicity caused by the BZL released from the 
CLNPs in a physiologic environment with the tumor microenvironment showed in cancer 
cells. For that, the growth inhibition effect of BZL-loaded CLNPs (at concentrations 
ranging from 5 to 100 µg/mL) was evaluated and compared with equal molar ratio of free 
BZL, a poorly water-soluble compound that was completely dissolved with 1% ethanol 
and diluted with cell culture media, after 24 h incubation (Figure 5.7 A-D). A similar 
trend on the antiproliferative effect of pure BZL and BZL-loaded CLNPs before and after 
functionalization was observed within the same cell line. Additionally, the half maximal 
inhibitory concentration (IC50) values were calculated for all the cell lines and are 
represented in Figure 5.7 E and detailed in Table S3. In general, when incubated with 
the three cancer cell lines, the CLNPs were more effective in decreasing the cell viability 
than the pure BZL, with reduced IC50. Here, the antiproliferative effect of the 
BZL@CLNPs showed the following general rate in cancer cell lines: BZL@CLNPs-
PEG-PHIS-CPP > BZL@CLNPs > BZL@CLNPs-CPP > pure BZL. The BZL@CLNPs-
PEG-PHIS-CPP presented a smaller IC50 (< 23.4 µM) than BZL@CLNPs (< 25.8 µM), 
BZL@CLNPs-CPP (< 29.1 µM) and pure BZL (< 37.5 µM). However, after incubation 
with EA.hy926 cells, the BZL@CLNPs-PEG-PHIS-CPP showed the highest IC50 (45.1 
µM), whereas the IC50 values for pure BZL, BZL@CLNPs and BZL@CLNPs-CPP were 
approximately 31 µM. This suggests that the coating with PEG-PHIS is decreasing the 
BZL release from the CLNPs-PEG-PHIS-CPP in physiologic environment, inducing less 
toxic effects to the normal cells.  




Overall, the BZL-loaded CLNPs showed an effective cell growth inhibition in all 
the cancer cell lines tested without using an organic solvent (e.g., ethanol) to solubilize 
the BZL, due to the enhanced solubility of BZL when loaded into CLNPs.  
Figure 5. 7 - Antiproliferative studies of (A) MDA-MB-231, (B) PC3-MM2, (C) Caco-2 and 
(D) EA.hy926 cell lines treated with pure BZL, previously dissolved with 1% ethanol, and 
BZL-loaded CLNPs. The samples were incubated at different concentrations in complete 
media, for 24 h at 37 °C. Errors bars represent the mean ± s.d. (n ≥ 3). (E) IC50 values 
obtained for BZL (blue), BZL@CLNPs (green), BZL@CLNPs-CPP (yellow) and 
BZL@CLNPs-PEG-PHIS-CPP (orange) after 24 h of incubation with the different cell lines 






In the present study, we have developed and characterized three innovative 
CLNPs: the bare CLNPs and two functionalized CLNPs (CLNPs-CPP and CLNPs-PEG-
PHIS-CPP), which presented round shape and moderately uniform dispersity. The 
success of the conjugation reactions was confirmed by ATR-FTIR and by the alteration 
of the ζ-potential values of the CLNPs after the conjugation reactions. All the CLNPs 
exhibited low cytotoxicity at concentrations up to at least 250 µg/mL in different cell lines 
at 24 h incubation. Concerning the drug loading capacity, our results indicate both the 
potential of using functionalized CLNPs to load a poorly water-soluble cytotoxic agent 
(BZL), and also the enhancement of its release profile in both pH 5.5 and 7.4, with higher 
release rates at acidic pH. Furthermore, the antiproliferative effect of BZL in the different 
cancer cell lines was enhanced after loading into CLNPs-PEG-PHIS-CPP, with lower 
IC50 values than BZL@CLNPs, BZL@CLNPs-CPP and pure BZL. However, when 
incubated with EA.hy926 cells, the BZL@CLNPs-PEG-PHIS-CPP showed the highest 
IC50, (45.1 µM), suggesting that the coating with PEG-PHIS can decrease the release of 
BZL from the CLNPs-PEG-PHIS-CPP in physiologic environment, causing less toxic 
effects to the normal cells. Overall, the functionalized CLNPs showed interesting 
properties for drug delivery and biomedical applications, including biocompatibility, 
good stability in biological media, and capability to load hydrophobic drugs and sustain 
their release. 
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8. Supporting Information 
 
8.1. Materials and Cell Culturing 
 
THF, HEPES and 2-(N-morpholino) ethanesulfonic acid (MES) were purchased 
from Sigma-Aldrich®, USA. Culture flasks were purchased from Corning Inc., USA. 
DMEM, Roswell Park Memorial Institute 1640 medium (RPMI), heat inactivated fetal 
bovine serum (FBS), L-glutamine (200 mM), non-essential amino acids (NEAA), 
penicillin (100 IU/mL), streptomycin (100 mg/mL), sodium pyruvate (100 mM) and 
trypsin (2.5%) were acquired from HyClone Waltham, USA. Dulbecco’s phosphate 
buffer saline (10× PBS) and Hank’s balanced salt solution (10× HBSS) were purchased 
from Life Technologies Gibco® (Carlsbad, CA, USA).  
Human umbilical vein cell line (EA.hy926), human mammary carcinoma cell line 
(MDA-MB-231), human prostate cancer cell line (PC3-MM2) and human colorectal 
adenocarcinoma cell line (Caco-2) were obtained from American Type Culture Collection 
(ATCC), USA. The EA.hy926, PC3-MM2 and Caco-2 cells were incubated in DMEM, 
and the MDA-MB-231 cells were incubated with RPMI, supplemented with 10% FBS, 
1% NEAA, 1% L-glutamine and 1% penicillin-streptomycin in 75 cm2 flasks. EA.hy926 
medium was also supplemented with 1% sodium pyruvate. Cells were maintained in an 
incubator (BB 16 gas incubator, Heraeus Instruments GmbH) at 37 ºC, 5% CO2 and 95% 
relative humidity. 
 
8.2. Synthesis of Poly(Ethylene Glycol)-Block-Poly(ι-
Histidine) (NH2-PEG-PHIS) 
 
The block copolymers were synthesized by direct coupling of the amine group of 
PHIS with the succinimidyl ester activated carboxylic group from Boc-NH-PEG-NHS 
(Figure S1 A). For that, PHIS was dissolved in 10 mM of HEPES to a concentration of 
2 mg/mL and the pH adjusted to 6.5. Two equivalents of Boc-NH-PEG-NHS were added 
to the solution with stirring. The reaction atmosphere was replaced with nitrogen gas in a 
round-bottom flask under stirring overnight. Then, the product of the reaction was 
purified by dialysis against deionized water, using a dialysis bag (MWCO of 8–10 kDa), 




replacing the exchange medium after 2, 4, 6, 12, 24, and 48 h. Subsequently, the purified 
product was freeze-dried. 
For the deprotection reaction, Boc-NH-PEG-PHIS was dissolved in a solution of 
95% TFA to a concentration of 5 mg/mL, and stirred for 1.5 h (Figure S1 B). Then, the 
TFA was neutralized first by diluting it four times with deionized water, followed by 
addition of 0.5 M of NaOH until reaching a neutral pH. The entire process was carried 
out in ice. Finally, the product of the reaction was purified by dialysis against deionized 
water, using a dialysis bag (MWCO of 8–10 kDa), replacing the exchange medium after 
2, 4, 6, 12, 24, and 48 h. Subsequently, the purified product NH2-PEG–PHIS was freeze-
dried (74). 
 
Table S 1 – HPLC conditions used in this study for quantification of the loaded 
and released BZL 
 BZL 
Mobile Phase (v/v) 
Solution A: 0.1% Trifluoroacetic acid 
(pH 2.0) 
Solution B: Acetonitrile 
(35:65) 
Column 
Kinetex® C18, 75×4.6 mm, 2.6 µm 
(Phenomenex, USA) 
Flow Rate (mL/min) 1.0 
Detection (UV, nm) 295 
Injection Volume (µL) 15 
Temperature (°C) 25 
Figure S 1 – Schematic representation of the synthesis of Poly(Ethylene Glycol)-
Block-Poly(ι-Histidine) (NH2-PEG-PHIS): A) Synthesis of Boc-NH-PEG-PHIS, and 
B) Deprotection of Boc-NH-PEG-PHIS 






Table S 2 – Description of the main lignin functional groups: IR absorption bands 
and respective type of vibration (78) 
IR band (cm-1) Type of vibration 
3500–3100 
Stretching vibrations of alcoholic and phenolic OH groups involved 
in hydrogen bonds 
2920–2850 Stretching vibrations of C–H bonds in methoxyl group 
1720 
Stretching vibrations of C=O bonds at β location and in unconjugated 
COOH group 
1600 Stretching vibrations of C=O bonds at α- and γ-locations 
1512 
Aromatic ring vibrations 1465 
1427 
1269 
Vibrations of guaiacyl rings and stretching vibrations of C–O bonds 
1215 
1150 Deformation vibrations of C–H bonds in guaiacyl rings 
1083 
Deformation vibrations of C–O bonds in secondary alcohols and 
aliphatic ethers 
1033 
Deformation vibrations of C–H bonds in the aromatic rings and 
deformation vibrations of C–O bonds in primary alcohols 
858 














23.1 ± 0.2 8.1 ± 1.0 20.4 ± 0.7 18.6 ± 0.2 
PC3-MM2 37.5 ± 1.2 25.8 ± 3.7 29.1 ± 1.3 21.1 ± 1.1 
Caco-2 24.4 ± 0.7 23.4 ± 2.3 28.1 ± 0.8 23.4 ± 0.9 
EA.hy926 31.5 ± 1.0 31.6 ± 1.6 31.6 ± 0.7 45.1 ± 2.2 
 
 
 
